Farm\u0101cijas gigants Pfizer veic v\u0113rien\u012bgu p\u0101r\u0146em\u0161anu svara samazin\u0101\u0161anas medikamentu tirg\u016b<\/p>\n
Farm\u0101cijas nozares milzis “Pfizer” ir uzs\u0101cis iespaid\u012bgu dar\u012bjumu, vienojoties par svara samazin\u0101\u0161anas medikamentu ra\u017eot\u0101ja “Metsera” ieg\u0101di. \u0160is dar\u012bjums, kas var\u0113tu sasniegt pat 7,3 miljardus dol\u0101ru, \u0146emot v\u0113r\u0101 iesp\u0113jamos n\u0101kotnes maks\u0101jumus, liecina par “Pfizer” strat\u0113\u0123isko l\u0113mumu nostiprin\u0101ties strauji augo\u0161aj\u0101 un aizvien popul\u0101r\u0101kaj\u0101 svara vad\u012bbas medikamentu tirg\u016b. \u0160is solis nav tikai par naudu, bet ar\u012b par vesel\u012bbas apr\u016bpes n\u0101kotnes veido\u0161anu un glob\u0101l\u0101s aptauko\u0161an\u0101s probl\u0113mas risin\u0101\u0161anu.<\/p>\n
Aptauko\u0161an\u0101s ir k\u013cuvusi par vienu no liel\u0101kaj\u0101m glob\u0101laj\u0101m vesel\u012bbas probl\u0113m\u0101m m\u016bsdien\u0101s, un piepras\u012bjums p\u0113c efekt\u012bviem un dro\u0161iem svara samazin\u0101\u0161anas risin\u0101jumiem ir milz\u012bgs. “Pfizer”, b\u016bdams viens no pasaules vado\u0161ajiem farm\u0101cijas uz\u0146\u0113mumiem ar pla\u0161u p\u0113tniec\u012bbas un att\u012bst\u012bbas potenci\u0101lu, ir apzin\u0101jies \u0161o milz\u012bgo iesp\u0113ju un nepiecie\u0161am\u012bbu. Ieg\u0101d\u0101joties “Metsera”, kas jau ir sevi pier\u0101d\u012bjusi inovat\u012bvu svara samazin\u0101\u0161anas medikamentu izstr\u0101d\u0113, “Pfizer” ieg\u016bst ne tikai eso\u0161os produktus, bet ar\u012b v\u0113rt\u012bgu pieredzi un tehnolo\u0123ijas, kas var pa\u0101trin\u0101t jaunu, v\u0113l efekt\u012bv\u0101ku z\u0101\u013cu rad\u012b\u0161anu.<\/p>\n
Strat\u0113\u0123isk\u0101 noz\u012bme un tirgus dinamika<\/p>\n
\u0160\u012b dar\u012bjuma strat\u0113\u0123isk\u0101 noz\u012bme ir ac\u012bmredzama. Svara samazin\u0101\u0161anas medikamentu tirgus, ko p\u0113d\u0113j\u0101s desmitgad\u0113s ir veicin\u0101ju\u0161as arvien pieaugo\u0161\u0101s aptauko\u0161an\u0101s probl\u0113mas vis\u0101 pasaul\u0113, ir piedz\u012bvojis spr\u0101dzienveida izaugsmi. Medikamenti, kas pal\u012bdz cilv\u0113kiem efekt\u012bvi un dro\u0161i zaud\u0113t svaru, ne tikai uzlabo vi\u0146u fizisko vesel\u012bbu, bet ar\u012b b\u016btiski ietekm\u0113 vi\u0146u pa\u0161v\u0113rt\u0113jumu un dz\u012bves kvalit\u0101ti. “Pfizer” sp\u0113kus \u0161aj\u0101 tirg\u016b var sal\u012bdzin\u0101t ar lielce\u013cu satiksmi \u2013 jo vair\u0101k ce\u013cu b\u016bs, jo vair\u0101k cilv\u0113ku var\u0113s nok\u013c\u016bt l\u012bdz savam m\u0113r\u0137im. \u0160obr\u012bd tirgus ir aizraujo\u0161s, un katrs sp\u0113l\u0113t\u0101js cen\u0161as ie\u0146emt savu ni\u0161u, nodro\u0161inot pacientiem arvien lab\u0101kus risin\u0101jumus.<\/p>\n
Analiz\u0113jot tirgus dinamiku, j\u0101atz\u012bm\u0113, ka ne tikai “Pfizer”, bet ar\u012b citi farm\u0101cijas giganti akt\u012bvi mekl\u0113 iesp\u0113jas papla\u0161in\u0101t savu kl\u0101tb\u016btni \u0161aj\u0101 segment\u0101. Konkurence ir s\u012bva, ta\u010du t\u0101 vienlaikus ar\u012b veicina inov\u0101cijas. Kad uz\u0146\u0113mumi konkur\u0113, pacienti ieg\u016bst \u2013 vi\u0146iem tiek pied\u0101v\u0101ti lab\u0101ki, dro\u0161\u0101ki un pieejam\u0101ki \u0101rst\u0113\u0161anas veidi. “Metsera” pievieno\u0161ana “Pfizer” portfelim dos iesp\u0113ju apvienot resursus un zin\u0101\u0161anas, lai rad\u012btu n\u0101kam\u0101s paaudzes medikamentus, kas var\u0113tu main\u012bt svara vad\u012bbas ainavu vis\u0101 pasaul\u0113. Tas ir k\u0101 gudrs sportists, kur\u0161 pievienojas sp\u0113c\u012bgai komandai, lai kop\u0101 sasniegtu v\u0113l liel\u0101kus m\u0113r\u0137us.<\/p>\n
N\u0101kotnes perspekt\u012bvas un potenci\u0101lais ieguvums<\/p>\n
\u0160\u012b p\u0101r\u0146em\u0161ana atver “Pfizer” durvis uz jauniem pacientu segmentiem un \u013cauj nostiprin\u0101t savas poz\u012bcijas vesel\u012bbas apr\u016bpes tirg\u016b, kas ir \u012bpa\u0161i svar\u012bgi main\u012bgaj\u0101 un izaicin\u0101jumiem bag\u0101taj\u0101 pasaul\u0113. Uz\u0146\u0113muma m\u0113r\u0137is ir ne tikai g\u016bt finansi\u0101lu labumu, bet ar\u012b sniegt iev\u0113rojamu ieguld\u012bjumu sabiedr\u012bbas vesel\u012bb\u0101, pied\u0101v\u0101jot risin\u0101jumus vienai no aktu\u0101l\u0101kaj\u0101m vesel\u012bbas probl\u0113m\u0101m. K\u0101 saprotams no CNBC zi\u0146\u0101m, \u0161is dar\u012bjums ir strat\u0113\u0123iski izsv\u0113rts solis, kura m\u0113r\u0137is ir nodro\u0161in\u0101t ilgtsp\u0113j\u012bgu izaugsmi un att\u012bst\u012bbu n\u0101kotn\u0113.<\/p>\n
Potenci\u0101lais ieguvums pacientiem ir milz\u012bgs. Ar papla\u0161in\u0101tajiem resursiem un p\u0113tniec\u012bbas jaudu, ko nodro\u0161ina “Pfizer”, “Metsera” var\u0113s pa\u0101trin\u0101t jaunu, inovat\u012bvu un efekt\u012bv\u0101ku svara samazin\u0101\u0161anas medikamentu izstr\u0101di un pieejam\u012bbu. Tas noz\u012bm\u0113 cer\u012bbu un re\u0101las iesp\u0113jas t\u016bksto\u0161iem, pat miljoniem cilv\u0113ku vis\u0101 pasaul\u0113, kuri c\u012bn\u0101s ar lieko svaru un ar to saist\u012btaj\u0101m vesel\u012bbas probl\u0113m\u0101m. \u0160is dar\u012bjums ir apliecin\u0101jums tam, ka farm\u0101cijas industrija sp\u0113j un v\u0113las risin\u0101t nopietnas sabiedr\u012bbas vesel\u012bbas probl\u0113mas, nodro\u0161inot jaunas un efekt\u012bvas \u0101rst\u0113\u0161anas metodes.<\/p>\n","protected":false},"excerpt":{"rendered":"Farm\u0101cijas gigants Pfizer veic v\u0113rien\u012bgu p\u0101r\u0146em\u0161anu svara samazin\u0101\u0161anas medikamentu tirg\u016b Farm\u0101cijas nozares milzis “Pfizer” ir uzs\u0101cis iespaid\u012bgu dar\u012bjumu,…\n","protected":false},"author":2,"featured_media":2347,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[77,76,1293,35,39,38,36,37,34,40,1291,1290,1292,787],"class_list":{"0":"post-2346","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-bizness","8":"tag-bizness","9":"tag-business","10":"tag-farmacijas-tirgus","11":"tag-latvia","12":"tag-latvian","13":"tag-latviesu","14":"tag-latviesu-valoda","15":"tag-latviesuvaloda","16":"tag-latvija","17":"tag-lv","18":"tag-metsera","19":"tag-pfizer","20":"tag-svara-samazinasanas-medikamenti","21":"tag-veselibas-aprupe"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/2346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/comments?post=2346"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/2346\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media\/2347"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media?parent=2346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/categories?post=2346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/tags?post=2346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}